Country: Singapore
Language: English
Source: HSA (Health Sciences Authority)
OLODATEROL HYDROCHLORIDE 0.002736 mg/actuation EQV OLODATEROL; TIOTROPIUM BROMIDE MONOHYDRATE 0.003124 mg/actuation EQV TIOTROPIUM
BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.
R03AL06
SOLUTION
OLODATEROL HYDROCHLORIDE 0.002736 mg/actuation EQV OLODATEROL 0.0025 mg/actuation; TIOTROPIUM BROMIDE MONOHYDRATE 0.003124 mg/actuation EQV TIOTROPIUM 0.0025 mg/actuation
RESPIRATORY (INHALATION)
Prescription Only
Boehringer Ingelheim Pharma GmbH & Co. KG
ACTIVE
2016-01-20
gji Abcd gji gji gji gji gji gji gji gji • gji gji gji gji Read the complete document
CCDS 0287-05 27082019 Abcd SPIOLTO RESPIMAT COMPOSITION The SPIOLTO RESPIMAT is a soft mist inhaler delivering tiotropium + olodaterol inhalation solution. The delivered dose is 2.5 microgram tiotropium and 2.5 microgram olodaterol per puff (2 puffs comprise one medicinal dose) and is equivalent to 3.124 microgram tiotropium bromide monohydrate and 2.7 microgram olodaterol hydrochloride. (INN = tiotropium bromide) (INN = olodaterol) The delivered dose is the dose which is available for the patient after passing the mouthpiece. Excipients**: Benzalkonium chloride, disodium edetate, water, purified, 1 M hydrochloric acid (for pH adjustment) INDICATIONS SPIOLTO RESPIMAT is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). DOSAGE AND ADMINISTRATION The recommended dose for adults is 5 microgram tiotropium and 5 microgram olodaterol given as two puffs from the Respimat inhaler once daily at the same time of the day (see Instructions for Use). Elderly Elderly patients can use SPIOLTO RESPIMAT at the recommended dose. Hepatic impairment and renal impairment SPIOLTO RESPIMAT contains tiotropium which is a predominantly renally excreted drug and olodaterol, which is predominantly metabolized in the liver. Hepatic impairment Patients with mild and moderate hepatic impairment can use SPIOLTO RESPIMAT at the recommended dose. There are no data available for use of olodaterol in patients with severe hepatic impairment. Renal impairment Renally impaired patients can use SPIOLTO RESPIMAT at the recommended dose. SPIOLTO RESPIMAT contains tiotropium, which is a predominantly renally excreted drug. For patients with moderate to severe impairment (creatinine clearance ≤ 50 ml/min, see SPECIAL WARNINGS AND PRECAUTIONS and PHARMACOKINETICS). CCDS 0287-05 27082019 Paediatric population There is no relevant use of SPIOLTO RESPIMAT in the paediatric population in COPD. The safety and effectiveness of SPIOLTO RESPIMAT in the paediatric populatio Read the complete document